AZD1222

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

COVID-19Liver Disease

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

1

AZD1222

AstraZeneca

Approved

132

Biaxin

AbbVie

Preclinical

23

Stivarga

Bayer

Preclinical

14

Aimovig

Amgen

Preclinical

15

Singulair

AstraZeneca

Preclinical

16

Calciferol

Alnylam Pharmaceuticals

Preclinical

—7

Angiomax

BBaxter Healthcare Corporation

Preclinical

28

Nitrostat

VViatris Specialty LLC

Preclinical

19

Low-Molecular-Weight Heparin

Daiichi Sankyo

Preclinical

310

SARS-COV-2 VACCINE

Moderna

Preclinical

2Show 17 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

COVID-1913 trials

Safety and Immunogenicity Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime Boost Regimen for the Prevention of Coronavirus Disease 2019 (COVID-19)

Completed·RR-Pharm·Phase 1/2·NCT04760730·100 enrolled

A Study to Evaluate the Safety and Immunogenicity of Booster With AZD1222, mRNA-1273, or MVC-COV1901 Against COVID-19

Completed·MMedigen Vaccine Biologics Corp.·Phase 2·NCT05197153·804 enrolled

Effectiveness of Covid-19 Vaccination in Eswatini Against SARS-CoV-2 Associated Hospitalization and Death

Completed·SShabir Madhi·Phase 4·NCT04914832·75,012 enrolled

Show 10 more trials

A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Compared With AZD1222 Against COVID-19 in Adults

Completed·MMedigen Vaccine Biologics Corp.·Phase 3·NCT05011526·1,030 enrolled

Immunogenicity and Safety of Fractional Booster Dose of COVID-19 Vaccines Available for Use in Pakistan/Brazil: A Phase 4 Dose-optimizing Trial

Completed·—·Phase 4·NCT05343871·2,354 enrolled

Open-label, Non-randomized, Non-comparative, Phase II Study of Safety and Immunogenicity of Combination of AZD1222 and rAd26-S for COVID-19 Prevention

Completed·RR-Pharm·Phase 2·NCT04686773·100 enrolled

Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults

Completed·AstraZeneca·Phase 3·NCT04516746·32,450 enrolled

Phase II/III Study of AZD2816, for the Prevention of COVID-19 in Adults

Completed·AstraZeneca·Phase 2/3·NCT04973449·2,843 enrolled

Study of AZD1222 for the Prevention of COVID-19 in Japan

Completed·AstraZeneca·Phase 1/2·NCT04568031·256 enrolled

AZD1222 Vaccine for the Prevention of COVID-19

Withdrawn·AstraZeneca·Phase 3·NCT04540393

COVID-19 Vaccines Safety Tracking (CoVaST)

Recruiting·MMasaryk University··NCT04834869·30,000 enrolled

A Study of AZD1222, a Vaccine for the Prevention of COVID-19 in Immunocompromised Adults

Terminated·AstraZeneca·Phase 4·NCT05057897·34 enrolled

Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime-Boost Regimen for the Prevention of COVID-19

Completed·RR-Pharm·Phase 1/2·NCT04684446·100 enrolled

Immunogenicity3 trials

COV-COMPARE Immunogenicity of Vaccine VLA2001 Compared to AZD1222

Completed·VValneva Austria GmbH·Phase 3·NCT04864561·4,034 enrolled

A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Vaccine Compared With AZD1222

Completed·MMedigen Vaccine Biologics Corp.·Phase 3·NCT05426343·200 enrolled

A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Compared With AZD1222 in Adults Aged 18 Years and Above

Completed·MMedigen Vaccine Biologics Corp.·Phase 3·NCT05198596·250 enrolled

Liver Disease1 trial

Antibody Response to COVID-19 Vaccines in Liver Disease Patients

Completed·HHumanity & Health Medical Group Limited·Phase 4·NCT04775069·232 enrolled

Unspecified1 trial

EU Secondary Data Post-Authorisation Safety Study of AZD1222

Completed·AstraZeneca··NCT05126992·5,321,930 enrolled

Details

Drug Info

Related News